Charlottesville, VA, United States
Charlottesville, VA, United States

Time filter

Source Type

Patent
GCS Inc | Date: 2016-10-20

One or more specific embodiments includes a method for providing an estimated formation pressure comprising modifying a first data set to derive a second data set that corresponds to estimated pressures wherein modifying the first data set comprises using a variable matrix factor and a compaction coefficient.


News Article | May 16, 2017
Site: www.prnewswire.com

Browse 72 market data Tables and 56 Figures spread through 140 Pages and in-depth TOC on "Unmanned Surface Vehicle (USV) Market" Early buyers will receive 10% customization on this report. This growth can be attributed to rising demand for maritime security, protection of shallow waters & ports, and need for ocean data & mapping, globally. "Defense segment expected to grow at the highest CAGR during the forecast period" The defense segment is expected to grow at a highest CAGR due to huge demand from navies across the world for purposes such as surveillance, reconnaissance, anti-submarine warfare, and mine countermeasures. Most of the players have invested into large sized USVs for combat operations, cargo supply, and lethal and non-lethal armament among others. "The sensors segment of the unmanned surface vehicle market is expected to grow at the highest CAGR during the forecast period" In terms of payload, the unmanned surface vehicle market has been segmented into sonars, sensors, camera, visual systems, INS, X-band radars, and others. The camera segment dominates the market. Cameras are cost-effective and provides ample opportunities for more advanced technological developments in near future. The sensor segment is projected to grow at the highest CAGR during the forecast period. "North America and European region show the highest potential for implementation of Unmanned Surface Vehicles" The unmanned surface vehicle market is dominated by North America, as of 2015, owing to the technological advancements and the growing terrorist activities in the region. The market is driven by increasing demand for water quality monitoring, ocean data mapping, asymmetric threats, and maritime security. In the European region, USVs are used in mine countermeasures (MCM) and focus is on to build new MCM-dedicated vessels. Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=220162588 The major players in this market have been identified to be ASV Unmanned Marine Systems (U.K.), Teledyne Technologies, Inc. (U.S.), Textron Inc. (U.S.), and Elbit Systems Ltd. (Israel), among others. Unmanned Underwater Vehicles (UUV) Market by Type (Remotely Operated Vehicle & Autonomous Underwater Vehicle), ROV & AUV Market by Application, by Product, by Propulsion System, by Payload & by Geography - Global Forecasts to 2020 http://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html Unmanned Aerial Vehicle (UAV) Market by Application, Class (Mini, Micro, Nano, Tactical, MALE, HALE, UCAV), SubSystem (GCS, Data Link, Software), Energy Source, Material Type, Payload and Region - Global Forecast to 2022 http://www.marketsandmarkets.com/Market-Reports/unmanned-aerial-vehicles-uav-market-662.html MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


News Article | May 16, 2017
Site: www.prnewswire.co.uk

Browse 72 market data Tables and 56 Figures spread through 140 Pages and in-depth TOC on "Unmanned Surface Vehicle (USV) Market" Early buyers will receive 10% customization on this report. This growth can be attributed to rising demand for maritime security, protection of shallow waters & ports, and need for ocean data & mapping, globally. "Defense segment expected to grow at the highest CAGR during the forecast period" The defense segment is expected to grow at a highest CAGR due to huge demand from navies across the world for purposes such as surveillance, reconnaissance, anti-submarine warfare, and mine countermeasures. Most of the players have invested into large sized USVs for combat operations, cargo supply, and lethal and non-lethal armament among others. "The sensors segment of the unmanned surface vehicle market is expected to grow at the highest CAGR during the forecast period" In terms of payload, the unmanned surface vehicle market has been segmented into sonars, sensors, camera, visual systems, INS, X-band radars, and others. The camera segment dominates the market. Cameras are cost-effective and provides ample opportunities for more advanced technological developments in near future. The sensor segment is projected to grow at the highest CAGR during the forecast period. "North America and European region show the highest potential for implementation of Unmanned Surface Vehicles" The unmanned surface vehicle market is dominated by North America, as of 2015, owing to the technological advancements and the growing terrorist activities in the region. The market is driven by increasing demand for water quality monitoring, ocean data mapping, asymmetric threats, and maritime security. In the European region, USVs are used in mine countermeasures (MCM) and focus is on to build new MCM-dedicated vessels. Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=220162588 The major players in this market have been identified to be ASV Unmanned Marine Systems (U.K.), Teledyne Technologies, Inc. (U.S.), Textron Inc. (U.S.), and Elbit Systems Ltd. (Israel), among others. Unmanned Underwater Vehicles (UUV) Market by Type (Remotely Operated Vehicle & Autonomous Underwater Vehicle), ROV & AUV Market by Application, by Product, by Propulsion System, by Payload & by Geography - Global Forecasts to 2020 http://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html Unmanned Aerial Vehicle (UAV) Market by Application, Class (Mini, Micro, Nano, Tactical, MALE, HALE, UCAV), SubSystem (GCS, Data Link, Software), Energy Source, Material Type, Payload and Region - Global Forecast to 2022 http://www.marketsandmarkets.com/Market-Reports/unmanned-aerial-vehicles-uav-market-662.html MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


News Article | May 15, 2017
Site: www.eurekalert.org

The Gauss Centre for Supercomputing (GCS) approved 30 large-scale projects during the 17th call for large-scale proposals, set to run from May 1, 2017 to April 30, 2018. Combined, these projects received 2.1 billion core hours, marking the highest total ever delivered by the three GCS centres -- the High Performance Computing Center Stuttgart (HLRS), Jülich Supercomputing Centre (JSC), and Leibniz Computing Centre of the Bavarian Academy of Sciences and Humanities (LRZ). In addition to delivering record-breaking allocation time, GCS also broke records in proposals received and number of allocations awarded. GCS awards large-scale allocations to researchers studying earth and climate sciences, chemistry, particle physics, materials science, astrophysics, and scientific engineering, among other research areas of great importance to society. Of the 30 projects, four were granted allocations exceeding 100 million core-hours -- another first for GCS -- speaking to users' increasingly strong command of making the best possible use of the various GCS centres' flagship supercomputers. "As we continue to provide world-class computing resources and user support at our three GCS facilities, our user base continues to expand based on the wide variety of excellent proposals we receive during each successive large-scale call," said Dr. Dietmar Kröner, University of Freiburg Professor and Chairman of the GCS Scientific Steering Committee. "We have tough decisions to make, as we only have so many core-hours per year, and the proposals continue to get better each year." Several of the largest allocations are benefiting from the variety of architectures offered through the three GCS centres. A team led by Dr. Matthias Meinke of RWTH Aachen University received a total of 335 million core hours--250 million at HLRS and 85 million at JSC--for a project dedicated to understanding turbulence, one of the last major unsolved fluid dynamics problems. The team studies turbulence as it relates to jet engine dynamics, and its research is focused on creating quieter, safer, more fuel efficient jet engines. A team of astrophysicists led by Dr. Hans-Thomas Janka of the Max Planck Institute for Astrophysics was granted 120 million core hours on LRZ's SuperMUC system to simulate supernovas--the death and explosion of stars, and one of the main ways that heavy elements travel across the universe. In previous allocations, the team was able to create one of the first first-principle simulations of a 3D supernova, and plans to expand its research to more accurately understand the volatile, dynamic processes that govern the formation of neutrinos and gravitational waves occurring after a supernova. Supercomputing has become an indispensable tool in studying the smallest, most fundamental building blocks of matter known to man--the quarks and gluons that make up protons and neutrons, and, in turn, our world. A research group based at the Department of Theoretical Physics at the University of Wuppertal is benefitting from two separate allocations--one of which uses both HLRS and JSC resources, while the other is solely based at JSC -- to more deeply understand the mysterious subatomic world: Dr. Szabolcs Borsányi leads a project aiming to make the first-ever estimate of sheer viscosity of the quark-gluon plasma--a novel state of matter that exists only at extremely high temperatures, making it very hard to study experimentally. The project was granted 35 million core hours on JSC's JUQUEEN. Prof. Dr. Zoltán Fodor was granted 130 million core-hours on HLRS's Hazel Hen and 78 million core-hours on JUQUEEN to support large-scale international experimental work being done at the Large Hadron Collider in Switzerland and the Relativistic Heavy Ion Collider in the United States. The team uses HPC to more fully understand phase transitions within quantum chromodynamics -- the behaviour of subatomic particles under extreme pressure or temperature conditions. For a complete list of projects, please visit: http://www. About GCS Large-Scale Projects: In accordance with the GCS mission, all researchers in Germany are eligible to apply for computing time on the petascale HPC systems of Germany's leading supercomputing institution. Projects are classified as "large-scale" if they are allocated more than 35 million core-hours in a given year at a GCS member centre's high-end system. Computing time is allocated by the GCS Scientific Steering Committee to ground-breaking projects which seek solutions to long-standing complex science and engineering process that cannot be solved without access to world-leading computing systems. The projects are evaluated through a strict peer review process on the basis of the project's scientific and technical excellence. More information on the application process for a large-scale project can be found at: http://www. About GCS: The Gauss Centre for Supercomputing (GCS) combines the three German national supercomputing centres HLRS (High Performance Computing Center Stuttgart), JSC (Jülich Supercomputing Centre), and LRZ (Leibniz Supercomputing Centre, Garching near Munich) into Germany's integrated Tier-0 supercomputing institution. Together, the three centres provide the largest, most powerful supercomputing infrastructure in all of Europe to serve a wide range of academic and industrial research activities in various disciplines. They also provide top-tier training and education for the national as well as the European High Performance Computing (HPC) community. GCS is the German member of PRACE (Partnership for Advanced Computing in Europe), an international non-profit association consisting of 24 member countries, whose representative organizations create a pan-European supercomputing infrastructure, providing access to computing and data management resources and services for large-scale scientific and engineering applications at the highest performance level. GCS is jointly funded by the German Federal Ministry of Education and Research and the federal states of Baden-Württemberg, Bavaria, and North Rhine-Westphalia. It is headquartered in Berlin, Germany.


Receive press releases from BIA of Southern California: By Email BIASC CEO to Speak at Trending Topics in Contracting for 2017 4th Annual Educational Symposium BIASC CEO Mike Balsamo, has been invited to speak on a panel at the Trending Topics in Contracting for 2017 4th Annual Educational Symposium on Thursday, April 27, 2017 at Brandman University, Irvine. Irvine, CA, April 27, 2017 --( The National Contract Management Association, Orange County will host the day-long educational, networking, and professional development event at the Brandman University in Irvine. The focus of the symposium is education and the best practices and guiding principles for contract management. Balsamo the joins the list of industry professionals at the Symposium along with Virginia Abadessa, Director of Contracts Administration and Materials Management at OCTA; Ryan Segarra Blaney, Esq., who manages contracts for the Advanced Technology Division of Southern California Edison; Lauren Casapulla Contracts Manager, Tecolote Research, Inc., Goleta, CA; Nick Sanders Manager, Government Compliance, General Atomics Aeronautical Systems, Inc., and Apogee Consulting, Inc.; Pamela L. Solis, CCCM, CFCM, CPCM, Fellow, Lead Manager, RRS Contracts, Harris Corp. – Electronic Systems; Dean G. Stathakis, Ph.D., Esq., Registered patent attorney and President/Chief Operations Officer of One3 IP Management; Glenn Sweatt, Esq., Counsel, Pillsbury Law, Palo Alto, CA, Government Contracts & Disputes Practice; and Edward Velasquez, CPCM, NCMA Fellow, President and CEO of Capitol GCS, Inc. About the Building Industry Association of Southern California, Inc.: BIASC is a full-service organization providing legislative advocacy, educational programming, labor relations, networking, and community relations. The association objective is to promote a positive business environment for the building industry. http://www.biasc.org/ Irvine, CA, April 27, 2017 --( PR.com )-- The Building Industry Association of Southern California, Inc. (BIASC) CEO Mike Balsamo has been invited to speak on a panel at the Trending Topics in Contracting for 2017 4th Annual Educational Symposium on Thursday, April 27, 2017 at Brandman University, Irvine. Balsamo will give a talk titled, Current Trends in Residential Construction Contracting, at 1:30 p.m.The National Contract Management Association, Orange County will host the day-long educational, networking, and professional development event at the Brandman University in Irvine. The focus of the symposium is education and the best practices and guiding principles for contract management.Balsamo the joins the list of industry professionals at the Symposium along with Virginia Abadessa, Director of Contracts Administration and Materials Management at OCTA; Ryan Segarra Blaney, Esq., who manages contracts for the Advanced Technology Division of Southern California Edison; Lauren Casapulla Contracts Manager, Tecolote Research, Inc., Goleta, CA; Nick Sanders Manager, Government Compliance, General Atomics Aeronautical Systems, Inc., and Apogee Consulting, Inc.; Pamela L. Solis, CCCM, CFCM, CPCM, Fellow, Lead Manager, RRS Contracts, Harris Corp. – Electronic Systems; Dean G. Stathakis, Ph.D., Esq., Registered patent attorney and President/Chief Operations Officer of One3 IP Management; Glenn Sweatt, Esq., Counsel, Pillsbury Law, Palo Alto, CA, Government Contracts & Disputes Practice; and Edward Velasquez, CPCM, NCMA Fellow, President and CEO of Capitol GCS, Inc.About the Building Industry Association of Southern California, Inc.:BIASC is a full-service organization providing legislative advocacy, educational programming, labor relations, networking, and community relations. The association objective is to promote a positive business environment for the building industry. http://www.biasc.org/ Click here to view the list of recent Press Releases from BIA of Southern California


CAMBRIDGE, Massachusetts, & OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) a annoncé aujourd'hui que les données provenant de deux essais cliniques de phase 1/2 évaluant NINLARO™ (ixazomib) chez des patients nouvellement diagnostiqués avec le myélome multiple seront présentés lors de sessions orales dans le cadre de la réunion annuelle 2017 de la European Hematology Association (EHA) qui se tiendra samedi 24 juin de 11:45 à 12:00 Heure d'été d'Europe centrale, et dimanche 25 juin de 8:15 à 8:30 Heure d'été d'Europe centrale. Les deux études ont évalué NINLARO plus lénalidomide et dexaméthasone chez les patients nouvellement diagnostiqués avec le myélome multiple n'ayant pas subi de greffe de cellules souches, suivis d'un traitement d'entretien à base de l'agent unique ixazomib. NINLARO n'est pas actuellement approuvé pour le traitement du myélome multiple nouvellement diagnostiqué ni dans le cadre d'un traitement d'entretien. "En dépit des progrès récents, le myélome multiple demeure un cancer hématologique rare, destructeur et incurable. Les données présentées dans le cadre de la réunion annuelle de la European Hematology Association (EHA) démontrent l'engagement continu de Takeda en faveur de l'exploration de nouvelles manières de fournir un traitement efficace et durable aux patients atteints de myélome multiple, à la fois au moment du diagnostic et en cas d'utilisation prolongée," a déclaré Jesus Gomez Navarro, M.D., Vice Président, Chef de la Recherche et du développement clinique en oncologie chez Takeda. Ces données de cette étude de Phase 1/2 démontre l'utilisation potentielle d'ixazomib combiné au lénalidomide-dexaméthasone dans le traitement du myélome multiple nouvellement diagnostiqué et dans le cadre d'une thérapie d'entretien à agent unique, qui a aboutit à l'obtention de réponses plus approfondies par les patients en cas d'utilisation continue du traitement. L'efficacité et le profil de sécurité d'ixazomib, associés à son administration entièrement orale, peuvent potentiellement réduire certaines charges logistiques et aider les patients à mener un traitement contre le myélome multiple," a-t-il ajouté. Des réponses profondes et durables ont été obtenues avec une dose hebdomadaire d'Ixazomib, plus Lénalidomide et Dexaméthasone chez des patients récemment diagnostiqués avec le myélome multiple: suivi à long terme des patients n'ayant pas subi de greffe de cellules souches (GCS) (Extrait S408, présentation orale à 11:45 Heure d'été d'Europe centrale le 24 juin 2017 au Salon IFEMA Madrid, Hall A) Dans cette étude de Phase 1/2, les patients nouvellement diagnostiqués avec le myélome multiple ont reçu une dose orale hebdomadaire d'ixazomib (1,68 - 3,95 mg/m2 en Phase 1 et 4,0 mg en Phase 2) plus lénalidomide et dexaméthasone, et ce, pendant jusqu'à douze cycles induction de 28 jours. 42 des 65 patients recrutés ont poursuivi par un traitement d'étude sans abandonner le traitement précocement en raison d'une greffe de cellules souches. Après le traitement initial, 25 patients ont commencé à recevoir un traitement hebdomadaire à base d'agent unique ixazomib, selon la dernière dose tolérée, administrée lors de l'induction jusqu'à la progression de la maladie ou l'apparition d'effets toxiques inacceptables. "L'ajout d'ixazomib – un inhibiteur oral du protéasome, premier de sa catégorie - au double traitement a montré qu'il permettait d'améliorer substantiellement l'efficacité du traitement chez les patients nouvellement diagnostiqués avec le myélome multiple," a affirmé Paul Richardson, M.D., du Dana-Farber Cancer Institute, chercheur principal. "Dans cet essai clinique de Phase 1/2 réalisé sur des patients nouvellement diagnostiqués avec le myélome multiple, un traitement à base d'ixazomib plus lénalidomide et dexaméthasone a abouti non seulement en une qualité de réponses supérieure, avec un calendrier posologique bi-hebdomadaire, mais également en un taux de réponses approfondi sur la durée, chez les patients n'ayant pas subi de greffe de cellules souches, ce qui est encourageant. En outre, un bénéfice clinique durable impressionnant a été constaté: les patients ont poursuivi avec un traitement d'entretien à base de l'agent unique ixazomib après un traitement par induction/ rémission réussi, grâce à cette approche uniquement orale," a-t-il ajouté. Le myélome multiple est un cancer des cellules plasmatiques de la moelle osseuse. Dans le myélome multiple, un groupe de cellules plasmatiques monoclonales, ou cellules myélomateuses, deviennent cancéreuses et se multiplient. Ces cellules plasmatiques malignes ont le potentiel d'affecter de nombreux os du corps, pouvant conduire à des fractures par tassement, des lésions osseuses lytiques et des douleurs connexes. Le myélome multiple peut entraîner un certain nombre de graves problèmes de santé touchant les os, le système immunitaire, les reins et les globules rouges, aboutissant notamment aux symptômes les plus courants de douleurs osseuses et de fatigue, signe d'anémie. Il s'agit d'une forme de cancer relativement rare, responsable chaque année d'environ 114.000 nouveaux cas à travers le monde. NINLAROTM (ixazomib) est un inhibiteur oral du protéasome également étudié dans le continuum des milieux de traitement du myélome multiple ainsi que de l'amyloïdose systémique à chaînes légères. Il est le premier inhibiteur oral du protéasome à avoir fait l'objet d'essais cliniques de Phase 3 et à être approuvé. NINLARO a été approuvé par la U.S. Food and Drug Administration (FDA) en november 2015, à la suite d'une revue prioritaire, et par la Commission européenne en novembre 2016. Aux Etats-Unis et en Europe, NINLARO est indiqué en combinaison avec le lénalidomide et dexaméthasone pour le traitement des patients atteints de myélome multiple qui ont reçu au moins un traitement antérieur. Une thrombocytopénie a été signalée avec NINLARO (28% contre 14%, dans les traitements à base de NINLARO et placébo, respectivement), le nadir des plaquettes se produisant généralement entre les jours 14 et 21 de chaque cycle de 28 jours, et le retour à la valeur de départ en début du cycle suivant. Ceci n'a pas abouti à une augmentation des événements hémorragiques ni des transfusions de plaquettes. Surveiller la numération plaquettaire au moins une fois par mois au cours du traitement à base de NINLARO et envisager une surveillance plus fréquente au cours des trois premiers cycles. Gérer avec des modifications de dose et des transfusions de plaquettes, conformément aux directives médicales standard. Des toxicités gastro-intestinales ont été relevées dans les traitements par NINLARO et placébo respectivement, tels la diarrhée (42% contre 36%), la constipation (34% contre 25%), la nausée (26% contre 21%) et les vomissements (22% contre 11%). Elles ont nécessité occasionnellement l'utilisation de médicaments antiémétiques et antidiarrhéiques, ainsi que de soins de soutien. Une neuropathie périphériquea été observée avec NINLARO (28% contre 21% dans les traitements à base de NINLARO et placébo, respectivement). La réaction la plus couramment rapportée était la neuropathie sensorielle périphérique (19% et 14% dans les traitements à base de NINLARO et placébo, respectivement). La neuropathie moteur périphérique n'a été signalée dans aucun des schémas thérapeutiques (< 1%). Surveiller les patients et rechercher les symptômes de neuropathie périphérique, et ajuster la dose si nécessaire. Un oedème périphériquea été signalé avec NINLARO (25% contre 18% dans les traitements à base de NINLARO et placébo, respectivement). Evaluer les patients et rechercher les causes sous-jacentes, puis fournir des soins de soutien si nécessaire. Ajuster la dose de dexaméthasone selon sa posologie, ou la dose de NINLARO en cas de symptômes graves. Les effets indésirables les plus fréquemment signalés (≥ 20%) au cours d'un traitement par NINLARO, et supérieurs à ceux rapportés dans le cas d'un placébo, étaient la diarrhée (42% contre 36%), la constipation (34% contre 25%), la thrombocytopénie (28% contre 14%), la neuropathie périphérique (28% contre 21%), la nausée (26% contre 21%), l'oedème périphérique (25% contre 18%), les vomissements (22% contre 11%) et les dorsalgies (21% contre 16%). Les événements indésirables graves signalés chez ≥ 2% des patients incluaient la thrombocytopénie (2%) et la diarrhée (2%). Pour chaque réaction indésirable, un ou plus des trois médicaments a été interrompu chez ≤ 1% des patients recevant NINLARO. Takeda Pharmaceutical Company Limited est une société pharmaceutique mondiale axée sur la R&D dont la mission est d’améliorer la santé et l’avenir des patients en traduisant la science en médicaments transformateurs. Takeda concentre ses efforts de recherche et de développement sur l’oncologie, la gastroentérologie et les domaines thérapeutiques du système nerveux central et les vaccins. Takeda réalise une R&D à la fois en interne et avec des partenaires pour se maintenir à l’avant-garde de l’innovation. Ses nouveaux produits innovants, notamment en oncologie et en gastroentérologie, ainsi que sa présence sur des marchés émergents, stimulent la croissance de Takeda. Plus de 30 000 employés de Takeda sont engagés à améliorer la qualité de vie des patients en collaborant avec ses partenaires du secteur des soins de santé dans plus de 70 pays. Pour de plus amples informations, veuillez visiter http://www.takeda.com/news.


— Global Steel Sandwich Panels Market 2012- 2022 Report provides detailed analysis of market in 9 chapters with required tables and figures. Access this report at https://www.themarketreports.com/report/global-steel-sandwich-panels-market-research-2011-2022 Global Steel Sandwich Panels Market report classifies Steel Sandwich Panels By Materials as EPS Panels, PU Panels, Glass Wool Panels and PF Panels. Applications covered in this report are Building Wall, Building Roof and Cold Storage. This report also provides key analysis for the geographical regions like Europe, North America, China, Japan & Korea. Companies like Kingspan, Metecno, Isopan, NCI Building Systems, TATA Steel, ArcelorMittal, Romakowski, Lattonedil, RigiSystems, Silex, Isomec, GCS, Zhongjie, AlShahin, Nucor Building Systems, Tonmat, Marcegaglia, Italpannelli and more are profiled in this report providing information on sale, price, sales regions, products and overview. Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/557009 Table of Contents: 1 Market Overview 1.1 Objectives of Research 1.2 Market Segment 2 Industry Chain 2.1 Industry Chain Structure 2.2 Upstream 2.3 Market 3 Environmental Analysis 3.1 Policy 3.2 Economic 3.3 Technology 3.4 Market Entry 4 Major Vendors 5 Market/Vendors Distribution 5.1 Regional Distribution 5.2 Product and Application 6 Regions Market 6.1 Global 6.2 Europe 6.3 North America 6.4 China 6.5 Japan & Korea 6.6 Trade 7 Forecast 7.1 Market Trends 7.2 Segment Forecast 8 Marketing Overview 8.1 Ex-factory Price 8.2 Buyer Price 8.3 Price Factors 8.4 Marketing Channel 9 Conclusion Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/557009 For more information, please visit https://www.themarketreports.com/report/global-steel-sandwich-panels-market-research-2011-2022%20


News Article | June 19, 2017
Site: www.eurekalert.org

With another decade of funding secured, GCS looks to invest in next-generation systems while strengthening comprehensive user support FRANKFURT, Germany, June 19, 2017 -- The Gauss Centre for Supercomputing (GCS) has secured funding for another decade of excellence and innovation in high-performance computing (HPC). Financed by the German Federal Ministry of Education and Research and the science ministries of Baden-Württemberg, Bavaria, and North Rhein-Westphalia, GCS is the umbrella organization of Germany's three national supercomputing facilities, the High Performance Computing Center Stuttgart, Jülich Supercomputing Centre (JSC), and Leibniz Supercomputing Centre (LRZ). The announcement comes at ISC17--one of the world's premier supercomputing conferences, taking place June 18-22 in Frankfurt, Germany. GCS is establishing its "smart exascale" decade by investing heavily in next-generation systems while also boosting the breadth and depth of how the centres support and collaborate with users. "Our number one priority is providing our users all the support needed to solve the world's most difficult scientific and engineering challenges," said Michael Resch, Chair of the GCS Board of Directors and Director of HLRS. "We will continue to deliver world-class supercomputing resources, but want to ensure that our user base in research and industry can take full advantage of these technologies." After receiving nearly €500 million for the next decade, GCS plans to greatly expand its training program, and is hiring more than 30 new staff members at the three centres for a variety of new support functions. The three GCS centres wanted to revamp the user support structure to include not only HPC support specialists, but also science domain experts. By having a contact versed in their various science domains, researchers using GCS resources can collaborate more closely with the respective centres and have a liaison available to help solve specific computing challenges in the researchers' specific areas of study. Fostering this kind of interdisciplinary, cross-organizational collaboration will nurture long-term research partnerships between some of Europe's preeminent researchers--currently fostered through GCS participation in the Partnership for Advanced Computing in Europe (PRACE) program--and its brightest supercomputing minds, ultimately helping solve the world's toughest science and engineering challenges while staying at technology's fore. This kind of end-to-end support is one of the most essential aspects of GCS' smart exascale vision. Exascale computing, a thousand-fold increase over current-generation petascale machines (capable of at least 1 quadrillion calculations per second, or a petaflop), promises researchers computing power to solve previously unsolvable problems, but also presents a whole new set of challenges for researchers to be able to take full advantage of the power next-generation machines offer. For GCS leadership, the success of exascale computing will come from not only delivering an exascale computer, but delivering the machine in an environmentally sustainable way while also providing a robust support system to ensure users from a wide variety of domains can make efficient use of these machines. To that end, GCS centres' staff will not only increase user support capabilities, but also diligently work on making application codes portable to a variety of computing platforms as well as developing new applications suited to next-generation architectures. "In the smart exascale decade, we will be thinking even more than before about people and education," said Claus-Axel Müller, Managing Director of GCS. About GCS: The Gauss Centre for Supercomputing (GCS) combines the three German national supercomputing centres HLRS (High Performance Computing Center Stuttgart), JSC (Jülich Supercomputing Centre), and LRZ (Leibniz Supercomputing Centre, Garching near Munich) into Germany's integrated Tier-0 supercomputing institution. Together, the three centres provide the largest, most powerful supercomputing infrastructure in all of Europe to serve a wide range of academic and industrial research activities in various disciplines. They also provide top-tier training and education for the national as well as the European High Performance Computing (HPC) community. GCS is the German member of PRACE (Partnership for Advanced Computing in Europe), an international non-profit association consisting of 24 member countries, whose representative organizations create a pan-European supercomputing infrastructure, providing access to computing and data management resources and services for large-scale scientific and engineering applications at the highest performance level. GCS is jointly funded by the German Federal Ministry of Education and Research and the federal states of Baden-Württemberg, Bavaria, and North Rhine-Westphalia. It is headquartered in Berlin, Germany. For more information, please visit http://www. .


"We delivered a record 424 shipsets compared to 408 shipsets in the same period last year, primarily driven by the ramp-up in production rates on the 737, the A320, and the A350 programs; our supply chain cost reduction initiatives are gaining traction; and we are finally fully-recovered in Kinston and back to our normal mode of sea transportation, following Hurricane Matthew last October," Spirit President and CEO Tom Gentile said. "In addition, Spirit recently made several announcements regarding the growth of our global fabrication business. We announced the creation of a new five-axis fabrication center of excellence and the expansion of our chemical processing capabilities on our Wichita, Kansas, campus. We also announced the creation of a new three- and four-axis fabrication center of excellence in McAlester, Oklahoma, and the expansion of our manufacturing facilities in Malaysia," Gentile added. "All of these initiatives solidify Spirit as a world leader in the fabrication of detailed parts for the commercial and military aerospace industry." "Importantly, we are pleased to announce the exciting news that we have reached an agreement with our largest customer, Boeing, into 2022 on open commercial issues related to a range of programs, including the 737 MAX and the 787. We have signed an MOU reflecting our agreement and will now be working on formal amendments to the program agreements," Gentile said. "Overall, by addressing a range of programs and not just 787 pricing, the MOU reduces much uncertainty that has long existed in the relationship with our largest customer and preserves our ability to meet our long-term cash flow goals," Gentile said. The MOU requires that the parties negotiate and execute Definitive Documentation, as defined in the MOU, in the third quarter of 2017. Spirit management believes the agreement will be completed and executed in the third quarter; however, there can be no assurance that Definitive Documentation will ultimately be executed and that Spirit's dispute with Boeing will be resolved pursuant to the MOU. "One of the biggest challenges in our discussions with Boeing has been 787 pricing. As part of this new MOU with Boeing, we are extending the block from 1003 units to 1300 units and establishing a planning block through line unit 1405. Although the 787 contract had agreed price step-downs for the 787-8, we had never agreed with Boeing on pricing for the 787-9 and -10. We have now agreed on modified step-down pricing for the 787-9 and -10 through line unit 1405. As a result of the MOU, we have recognized a reach-forward loss of $353 million on the 787 program," Gentile remarked. "The agreement also includes a commitment from both organizations to work together on joint cost reduction efforts with financial incentives for both parties," Gentile added. "In addition to addressing open commercial issues, Spirit has also agreed with Boeing that we will jointly study advanced aerostructures and manufacturing processes," Gentile said. Spirit's second quarter 2017 revenue was $1.8 billion, consistent with the same period of 2016, primarily driven by higher production deliveries on the Boeing 737 and Airbus A350 XWB programs, offset by lower production deliveries on the Boeing 777 program and decreased Global Customer Support & Services (GCS&S) activity. (Table 1) Spirit's backlog at the end of the second quarter of 2017 was approximately $46 billion, with work packages on all commercial platforms in the Boeing and Airbus backlog. Operating income for the second quarter of 2017 was $(82.8) million, down compared to $83.3 million in the same period of 2016, reflecting the impact of the MOU with Boeing, partially offset by increased sales on higher-profit programs and the reversal of a litigation reserve, as well as the absence of the charges recognized during the second quarter of 2016 associated with the Airbus settlement. Second quarter reported EPS was $(0.48), or $1.57* per share adjusted to exclude the impact of the MOU with Boeing, compared to $0.35 EPS (or $1.21* adjusted) in the same period of 2016. (Table 1) "Given the strong performance in the first half of 2017, we are raising our full-year adjusted earnings per share* guidance by $0.40 to a new range of $5.00 - $5.25 per share from the previous guidance range of $4.60 - $4.85," Gentile said. Free cash flow* in the second quarter of 2017 was $175 million, up 9 percent compared to free cash flow of $161 million in the same quarter last year. (Table 2) "Additionally, we are raising our free cash flow* guidance to $500-$550 from the previous range of $450-$500," Gentile added. Cash balance at the end of the quarter was $697 million. The company's $650 million revolving credit facility remained undrawn at the end of the quarter. "In the second quarter, we repurchased 2.2 million shares for $126 million. Year-to-date we have deployed a total of $208 million and repurchased 3.6 million shares under the existing authorization of up to $600 million," Gentile concluded. "The Board has authorized an increase in our share repurchase program of $400 million, resulting in a total program authorization of $1 billion. With the shares repurchased in the first half of 2017, we have approximately $800 million of this authorization remaining." Financial Outlook and Risk to Future Financial Results Risks applicable to our financial guidance are described more fully in the Cautionary Statement Regarding Forward-Looking Statements in this release. Fuselage Systems segment revenue in the second quarter of 2017 increased by 2 percent from the same period last year to $938 million, primarily due to higher production deliveries on the Boeing 737 and increased defense-related activity, partially offset by lower production deliveries on the Boeing 777 program and lower GCS&S activity. Operating margin for the second quarter of 2017 decreased to (8.5) percent, compared to 2.3 percent during the same period of 2016, primarily due to the impact from the MOU with Boeing. Additionally, the second quarter 2016 operating margin was impacted by the forward loss charge recognized on the Airbus A350 XWB program during the second quarter of 2016, which resulted from the Airbus settlement. In the second quarter of 2017, the segment recorded pretax $0.7 million of favorable cumulative catch-up adjustments and net forward losses of $(231.7) million. Propulsion Systems segment revenue in the second quarter of 2017 decreased 9 percent from the same period last year to $437 million, primarily driven by lower production deliveries on the Boeing 777 program, lower revenue recognized on the Boeing 787 program, and decreased GCS&S activity, partially offset by higher production deliveries on the Boeing 737. Operating margin for the second quarter of 2017 was 9.4 percent, compared to 15.4 percent during the same period of 2016, primarily driven by the impact from the MOU with Boeing. In the second quarter of 2017, the segment recorded pretax $6.1 million of favorable cumulative catch-up adjustments on mature programs and net forward losses of $(48.0) million. Wing Systems segment revenue in the second quarter of 2017 increased by 6 percent from the same period last year to $451 million, primarily due to higher production deliveries on the Airbus A350 XWB and A320, as well as higher revenue recognized on the Boeing 787 program, partially offset by the absence of one-time claim settlements with customers that took place in the second quarter of 2016. Operating margin for the second quarter of 2017 decreased to 6.8 percent, compared to 15.3 percent during the same period of 2016, primarily due to the MOU with Boeing. In the second quarter of 2017, the segment recorded pretax $17.5 million of favorable cumulative catch-up adjustments primarily on mature programs and net forward losses of $(73.8) million. * Non-GAAP financial measure, see Appendix for reconciliation This press release contains "forward-looking statements" that may involve many risks and uncertainties. Forward-looking statements reflect our current expectations or forecasts of future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "aim," "anticipate," "believe," "could," "continue," "estimate," "expect," "goal," "forecast," "intend," "may," "might," "objective," "plan," "predict," "project," "should," "target," "will," "would," and other similar words, or phrases, or the negative thereof, unless the context requires otherwise. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties, both known and unknown. Our actual results may vary materially from those anticipated in forward-looking statements. We caution investors not to place undue reliance on any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in such forward-looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the 787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus' production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of potential changes in tax law, such as those outlined in recent proposals on U.S. tax reform; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain highly-skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and borrowing facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our existing senior revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; and 30) exposure to potential product liability and warranty claims; and (31) our ability to successfully negotiate and execute with Boeing, Definitive Documentation, as defined in the MOU, to implement the MOU in the third quarter of 2017. These factors are not exhaustive and it is not possible for us to predict all factors that could cause actual results to differ materially from those reflected in our forward-looking statements. These factors speak only as of the date hereof, and new factors may emerge or changes to the foregoing factors may occur that could impact our business. As with any projection or forecast, these statements are inherently susceptible to uncertainty and changes in circumstances. Except to the extent required by law, we undertake no obligation to, and expressly disclaim any obligation to, publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information concerning these and other factors can be found in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. In addition to reporting our financial information using U.S. Generally Accepted Accounting Principles (GAAP), management believes that certain non-GAAP measures (which are indicated by * in this report) provide investors with important perspectives into the company's ongoing business performance. The company does not intend for the information to be considered in isolation or as a substitute for the related GAAP measures. Other companies may define the measures differently. Free cash flow is defined as GAAP net cash provided by operating activities (cash flow from operations), less capital expenditures for property, plant and equipment additions. Management believes free cash flow provides investors with an important perspective on the cash available for shareholders, debt repayment, and acquisitions after making the capital investments required to support ongoing business operations and long term value creation. Free cash flow does not represent the residual cash flow available for discretionary expenditures as it excludes certain mandatory expenditures such as repayment of maturing debt. Management uses free cash flow as a measure to assess both business performance and overall liquidity. Management considers special items, which may include termination charges, settlement charges and other items that arise from time to time, to be outside the ordinary course of our operations. Management believes that excluding these items provides a better understanding of the underlying trends in the company's operating performance and allows more accurate comparisons of the company's operating results to historical performance. Accordingly, Adjusted Free Cash Flow is defined as free cash flow less these special items. The table below provides reconciliations between the GAAP and non-GAAP measures.


Grant
Agency: National Science Foundation | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 174.46K | Year: 2010

This Small Business Innovation Research Phase I project will create a microcarrier with immobilized growth factors for adherent cultured cells. This advancement in cell culture biomaterials promises to remove the variability associated with growth factors in liquid media while increasing cell culture workflow efficiency. The project is to identify an efficient reaction mechanism for coupling protein, including animal serum and purified fibroblast growth factor (FGF), to the surface of a previously developed magnetic alginate microcarrier. The resulting product is anticipated to have significant benefits over traditional flask culture methods and will provide enabling technology to next generation drug discovery and therapeutics as primary and stem cells become the cell types of choice. The broader impact/commercial potential of this project is the use of immobilized growth factors to advance the basic understanding of cell-substrate interactions. Currently, the major cost for culturing primary and stem cells is the cell growth media, which contains costly purified growth factors. Reducing the amount of growth factors necessary for culture will directly reduce the cost per cell. Furthermore, this product will prove valuable for therapeutic applications including cell-based therapies in which cGMP growth factors would be especially costly. Finally, a growth factor-conjugated microsphere will be a useful basic research platform for understanding the role of "immobilized" growth factors in vivo, which is important for creating bio-scaffolds and regenerative implants.

Loading GCS Inc collaborators
Loading GCS Inc collaborators